

# Lisa Licitra

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3101675/lisa-licitra-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50  
papers

1,942  
citations

14  
h-index

44  
g-index

56  
ext. papers

2,856  
ext. citations

6.7  
avg, IF

4.04  
L-index

#	Paper	IF	Citations
50	Angiogenesis inhibition in lung cancer: emerging novel strategies. <i>Current Opinion in Oncology</i> , <b>2022</b> , 34, 107-114	4.2	0
49	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. <i>European Journal of Cancer</i> , <b>2021</b> , 159, 194-204	7.5	6
48	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 17-26	7.5	1
47	The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation. <i>Oral Oncology</i> , <b>2021</b> , 114, 105128	4.4	2
46	Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
45	Next generation platinum salt in nasopharyngeal carcinoma. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 577-578	21.7	
44	Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients. <i>Acta Oncologica</i> , <b>2021</b> , 60, 1192-1200	3.2	1
43	A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
42	History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
41	An Old but Still Unanswered Question in Recurrent or Metastatic Salivary Duct Carcinoma.. <i>JCO Precision Oncology</i> , <b>2021</b> , 5, 1526-1527	3.6	1
40	The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis. <i>Oral Oncology</i> , <b>2021</b> , 121, 105454	4.4	2
39	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , <b>2021</b> , 157, 250-258	7.5	6
38	Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 164, 1-5	5.3	3
37	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
36	Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, e350-e359	21.7	62
35	Low skeletal muscle mass as predictor of postoperative complications and decreased overall survival in locally advanced head and neck squamous cell carcinoma: the role of ultrasound of rectus femoris muscle. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2020</b> , 277, 3489-3502	3.5	7
34	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 35-42	7.5	8

33	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. <i>Cancers</i> , <b>2020</b> , 12,	6.6	15
32	Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700). <i>Oncology</i> , <b>2020</b> , 98, 763-770	3.6	4
31	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. <i>Cells</i> , <b>2020</b> , 9,	7.9	6
30	A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 2479-2487	4.9	3
29	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. <i>Laryngoscope</i> , <b>2020</b> , 130, 857-865	3.6	10
28	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy <b>2020</b> , 15, e0232639		
27	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy <b>2020</b> , 15, e0232639		
26	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy <b>2020</b> , 15, e0232639		
25	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy <b>2020</b> , 15, e0232639		
24	Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. <i>Oral Oncology</i> , <b>2019</b> , 97, 82-91	4.4	3
23	Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 837	5.3	8
22	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. <i>BioMed Research International</i> , <b>2019</b> , 2019, 9056417	3	28
21	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. <i>Oral Oncology</i> , <b>2019</b> , 90, 94-101	4.4	7
20	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. <i>Dysphagia</i> , <b>2019</b> , 34, 52-62	3.7	5
19	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. <i>Oral Oncology</i> , <b>2019</b> , 95, 106-114	4.4	11
18	Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 2517-2528.e28	3.5	1
17	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , <b>2019</b> , 394, 1915-1928	4.0	839
16	PD-1 immunotherapy for recurrent or metastatic HNSCC. <i>Lancet, The</i> , <b>2019</b> , 394, 1882-1884	4.0	5

15	Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , <b>2019</b> , 41, 1895-1902	4.2	5
14	International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV. <i>Head and Neck</i> , <b>2019</b> , 41, 1725-1737	4.2	36
13	Treatment challenges in and outside a network setting: Head and neck cancers. <i>European Journal of Surgical Oncology</i> , <b>2019</b> , 45, 40-45	3.6	21
12	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , <b>2018</b> , 81, 45-51	4.4	372
11	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. <i>Therapeutic Advances in Medical Oncology</i> , <b>2018</b> , 10, 1758835918762094	5.4	74
10	Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 100, 1217-1221	4	9
9	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 65, 78-86	14.4	24
8	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. <i>European Journal of Cancer</i> , <b>2018</b> , 93, 89-98	7.5	7
7	Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. <i>Oral Oncology</i> , <b>2018</b> , 82, 144-151	4.4	11
6	In Reply to Fakhry et al. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 670-671	4	1
5	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. <i>Oral Oncology</i> , <b>2018</b> , 86, 266-272	4.4	17
4	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 323-335	21.7	133
3	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. <i>Oral Oncology</i> , <b>2017</b> , 69, 33-37	4.4	14
2	Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. <i>Oncologist</i> , <b>2017</b> , 22, 1056-1066	5.7	80
1	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 72	5.3	86